Cases of a rare autoimmune disease surged between 2020 and 2022 in Yorkshire, England, peaking in 2021. COVID-19 infection and its vaccines possibly contributed to the rise, a recent study in The Lancet’s eBioMedicine found.
The disease — melanoma differentiation-associated protein-5 (anti-MDA5) positive dermatomyositis, or anti-MDA5 dermatomyositis — is an inflammatory disease characterized by muscle weakness, skin rashes, and rapidly progressive lung disease.
In 2019, Yorkshire, which has a population of 3.6 million, reported two people testing positive for the disease. In 2020, there were nine. Cases peaked in 2021 with 35 new cases. The number then dropped to 16 new cases in 2022.
The new autoimmune cases may have arisen from the COVID-19 virus and vaccine RNA interactions, the study’s senior author, Dr. Dennis McGonagle, clinical professor of medicine at the University of Leeds, told The Epoch Times.
Dermatomyositis tends to affect the skin, muscles, and lungs. Anti-MDA5 dermatomyositis involves rapidly progressive lung disease, which lends the condition a poor prognosis.
MDA5 is a protein present outside of muscles and tissues, especially prominent in the lungs. Therefore, when the body forms anti-MDA5 antibodies to attack MDA5, it can deteriorate related organs and tissues.
MDA5 can detect and bind to foreign RNA, including COVID-19 RNA. Upon detection, it signals other immune cells to fight the foreign invader or vaccination.
We think that … [this happens] because MDA5 is the receptor or docking site for viral RNA, and that this in some way triggers the antibody against it, Dr. McGonagle said.
In a COVID-19 infection, MDA5’s binding to RNA can result in too much MDA5 activity as a response, Dr. Pradipta Ghosh, director of the Institute for Network Medicine at the University of California-San Diego and another corresponding author of the study, told The Epoch Times.
COVID-19 patients were shown to have high MDA5 gene activity in their lung fluids, further suggesting that the virus might have triggered new MDA5 cases.
Apart from anti-MDA5, 15 other autoantibodies can contribute to similar dermatomyositis diseases. The role of MDA5 in COVID-19 infection and vaccination may explain why, during the pandemic, only anti-MDA5 dermatomyositis cases increased while other autoantibodies involved in dermatomyositis did not.
Between 2020 and 2022, all 60 new anti-MDA5 dermatomyositis patients in Yorkshire were evaluated. All developed symptoms.
Over 40 percent developed interstitial lung disease and had a worse prognosis. Half died by the time the study was published.
The authors noted that anti-MDA5 cases during the pandemic presented slightly differently than pre-pandemic cases.
Compared to pre-pandemic, anti-MDA5 cases reported during the pandemic had a lower rate of lung disease and a lower death rate, said Dr. Ghosh. The disease also affected white people as opposed to Asians, who were the more predominant demographic previously.
Around 90 percent of the Yorkshire population was vaccinated, and 49 of the 60 cases had documented COVID-19 vaccination.
Contrastingly, only 15 out of 60 had had a confirmed COVID-19 infection.
The authors argued that MDA5, which is involved in the activation of various cytokines, may precipitate inflammatory reactions when exposed to SARS-CoV-2.
However, Dr. Ghosh said that while spike protein has been implicated in other autoimmune diseases, anti-MDA5 disease is caused by antibodies against MDA5, not spike.
I believe that we have a lot of work to do before we can begin to understand why or how our body responds to this virus, its particles, its RNA/protein — even the RNA encoding its key components we use as vaccine in the plethora of ways that it does, she explained.
